Sethi Leads UB’s Clinical Trial of REGN-COV2

Updated November 20, 2020

Researchers — including Sanjay Sethi, MD, professor of medicine and chief of the Division of Pulmonary, Critical Care and Sleep Medicine — are recruiting household members of individuals who have tested positive for COVID-19 to enroll in a study of Regeneron’s national clinical trial of the investigational antibody cocktail REGN-COV2. The monoclonal antibody treatment is believed to reduce the severity of symptoms in individuals exposed to COVID-19 or possibly even prevent symptoms entirely.